C3, Equipmed sign distribution agreements

By Melissa Trudinger
Monday, 27 October, 2003

Perth-based tissue engineering company Clinical Cell Culture (C3, ASX: CCE) has signed distribution agreements with Equipmed to distribute C3's CellSpray and ReCell products in Australia, excluding Western Australia, and New Zealand.

The ReCell agreement will be activated once TGA approval has been obtained for general marketing of the product. The agreements have three year terms and including marketing and support activities.

C3 CEO Troels Jordansen said the company was pleased to have an agreement with Equipmed, which has experience in the plastic and cosmetic surgery market and distributes tissue engineering products from international company Isolagen.

C3 is planning to expand its business internationally next year, with a European production facility in the works and sales of ReCell in 15 companies around the world expected.

Related News

The University of Sydney formalises cervical cancer elimination partnership

The success of a cervical cancer elimination program has led to the signing of a memorandum of...

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd